WJNS  Vol.4 No.5 , November 2014
Safety and Tolerability of Transdermal Rotigotine in a Clinical Practice Cohort for 2 Years
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease that occurs as a result of loss of dopaminergic neurons from the substantia nigra. Rotigotine is a non-ergolinic dopamine agonist available as a silicone-based transdermal patch for the treatment of PD. In the European Union, rotigotine transdermal patch is indicated for use as monotherapy in early idiopathic PD, or in combination with levodopa through the disease course to the late stages where motor complications with levodopa become an issue. Objective: To investigate the safety and tolerability of transdermal rotigotine, in patients with PD being treated during routine clinical practice for 2 years. Results: 114 patients were enrolled, and evaluated for adverse events over a 24-month period. Adverse events occurred in 39 patients (34.21%). 23 patients (20.17%) reported application site reactions (dermatitis, erythema, itching), and 16 (14.03%) had systemic adverse events. Sleep disorders were the most common problem; the others were hallucinations, depression, dizziness, and syncope. No patient experienced dyskinesia. Adverse events necessitated the discontinuation of rotigotine for application site reactions in fourteen patients (12.28%) and 11 patients (9.64%); reasons for discontinuation were systemic adverse events. Conclusion: Rotigotine is safe and well tolerated when used to treat PD in routine clinical practice.

Cite this paper
Constenla, I. , Pato, A. , Hernando, I. and Gonzalez, J. (2014) Safety and Tolerability of Transdermal Rotigotine in a Clinical Practice Cohort for 2 Years. World Journal of Neuroscience, 4, 443-449. doi: 10.4236/wjns.2014.45050.
[1]   Lang, A.E. and Obeso, J.A. (2004) Challenges in Parkinson’s Disease: Restoration of the Nigrostriatal Dopamine System Is Not Enough. The Lancet Neurology, 3, 309-316. http://dx.doi.org/10.1016/S1474-4422(04)00740-9

[2]   Silver, D. (2006) Impact of Functional Age on the Use of Dopamine Agonists in Patients with Parkinson Disease. Neurologist, 12, 214-223. http://dx.doi.org/10.1097/01.nrl.0000215782.78763.fa

[3]   European Medicines Agency (2012) Neupro 2 mg/24h transdermal Patch: Summary of Product Characteristics [Online]. http://www.emea.europa.eu/2012docs/en_GB/document_library/EPAR_-_Product_Information/human/000626/WC500026397.pdf

[4]   Giladi, N., Surmann, E. and Boroojerdi, B. (2011) The Safety and Efficacy of Transdermal Rotigotine over a 6-Year Period in Patients with Early-Stage Idiopathic Parkinson’s Disease: SP716 Study Group. Movement Disorders, 26, 128-129.

[5]   LeWitt, P.A., Boroojerdi, B., Poewe, W., et al. (2010) Long-Term Treatment of Advanced Parkinsons Disease with Rotigotine. Neurology, 74, A350. [Abstract]

[6]   Watts, R.L., Boroojerdi, B. and Jankovic, J. (2010) Open-Label Extension Trial Assessing the Effects of Long-Term Treatment with Rotigotine in Subjects with Early-Stage, Idiopathic Parkinson’s Disease: Results from up to 7 Years. Movement Disorders, 25, S310-S311. [Abstract No. 386]

[7]   Elmer, L.W., Surmann, E., Boroojerdi, B., et al. (2012) Long-Term Safety and Tolerability of Rotigotine Transdermal System in Patients with Early-Stage Idiopathic Parkinson’s Disease: A Prospective, Open-Label Extension Study. Parkinsonism & Related Disorders, 18, 488-493.

[8]   Gelb, D.J., Oliver, E. and Gilman, S. (1999) Diagnostic Criteria for Parkinson Disease. Archives of Neurology, 56, 33-39.

[9]   LeWitt, P.A., Lyons, K.E. and Pahwa, R. (2007) Advanced Parkinson Disease Treated with Rotigotine Transdermal System: PREFER Study. Neurology, 68, 1262-1267.

[10]   Giladi, N., Boroojerdi, B., Korczyn, A.D., et al. (2007) Rotigotine Transdermal Patch in Early Parkinson’s Disease: A Randomized, Double-Blind, Controlled Study versus Placebo and Ropinirole. Movement Disorders, 22, 2398-2404.

[11]   The Parkinson Study Group (2003) A Controlled Trial of Rotigotine Monotherapy in Early Parkinson’s Disease. Archives of Neurology, 60, 1721-1728. http://dx.doi.org/10.1001/archneur.60.12.1721

[12]   Watts, R.L., Jankovic, J., Waters, C., Rajput, A., Boroojerdi, B. and Rao, J. (2007) Randomized, Blind, Controlled Trial of Transdermal Rotigotine in Early Parkinson Disease. Neurology, 68, 272-276.

[13]   Poewe, W.H., Rascol, O., Quinn, N., Tolosa, E., Oertel, W.H., Martignoni, E., et al. (2007) Efficacy of Pramipexole and Transdermal Rotigotine in Advanced Parkinson’s Disease: A Double-Blind, Double-Dummy, Randomised Controlled Trial. The Lancet Neurology, 6, 513-520.

[14]   Trenkwalder, C., Kies, B., Rudzinska, M., Fine, J., Nikl, J., Honczarenko, K., et al. (2011) Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson’s Disease: A Double-Blind, Randomized, Placebo-Controlled Study (RECOVER). Movement Disorders, 26, 90-99.

[15]   Ghys, L., LeWitt, P.A., Grieger, F., et al. (2010) Treatment of Patients with Early and Advanced Parkinson’s Disease (PD) with Transdermal Rotigotine: Age Relationship to Safety and Tolerability. Proceedings of the 7th International Congress on Mental Dysfunctions and Other Non-Motor Features in Parkinson’s Disease and Related Disorders, Barcelona, 9-12 December 2010, Abstract.

[16]   Jankovic, J., Watts, R.L., Martin, W. and Boroojerdi, B. (2007) Transdermal Rotigotine: Double-Blind, PlaceboControlled Trial in Parkinson Disease. Archives of Neurology, 64, 676-682.

[17]   Chen, J.J., Swope, D.M., Dashtipour, K. and Lyons, K.E. (2009) Transdermal Rotigotine: A Clinically Innovative Dopamine-Receptor Agonist for the Management of Parkinson’s Disease. Pharmacotherapy, 29, 1452-1467.

[18]   Wingo, T.S., Evatt, M., Scott, B., Freeman, A. and Stacy, M. (2009) Impulse Control Disorders Arising in 3 Patients Treated with Rotigotine. Clinical Neuropharmacology, 32, 59-62.

[19]   Garcia-Ruiz, P.J., Martinez Castrillo, J.C., Alonso-Canovas, A., Herranz Barcenas, A., Vela, L., Sanchez Alonso, P., Mata, M., Olmedilla Gonzalez, N. and Mahillo Fernandez, I. (2014) Impulse Control Disorder in Patients with Parkinson’s Disease under Dopamine Agonist Therapy: A Multicentre Study. Journal of Neurology, Neurosurgery, and Psychiatry, 85, 840-844.

[20]   Ceballos-Baumann, A. and Hack, H.J. (2011) Rotigotine Transdermal Patch in Combination Therapy for Parkinson’s Disease-Observations in Routine Clinical Practice. Current Medical Research and Opinion, 27, 1899-1905.

[21]   Schnitzler, A., Leffers, K.W. and Hack, H.J. (2010) High Compliance with Rotigotine Transdermal Patch in the Treatment of Idiopathic Parkinson’s Disease. Parkinsonism & Related Disorders, 16, 513-516.

[22]   Babic, T., Boothmann, B., Polivka, J., Rektor, I., Boroojerdi, B., Hack, H.-J. and Randerath, O. (2006) Rotigotine Transdermal Patch Enables Rapid Titration to Effective Doses in Advanced-Stage Idiopathic Parkinson Disease: Subanalysis of a Parallel Group, Open-Label, Dose-Escalation Study. Clinical Neuropharmacology, 29, 238-242.

[23]   Giladi, N., Fichtner, A., Poewe, W. and Boroojerdi, B. (2010) Rotigotine Transdermal System for Control of Early Morning Motor Impairment and Sleep Disturbances in Patients with Parkinson’s Disease. Journal of Neural Transmission, 117, 1395-1399. http://dx.doi.org/10.1007/s00702-010-0506-4

[24]   Guldenpfennig, W.M., Poole, K.H., Sommerville, K.W. and Boroojerdi, B. (2005) Safety, Tolerability, and Efficacy of Continuous Transdermal Dopaminergic Stimulation with Rotigotine Patch in Early-Stage Idiopathic Parkinson Disease. Clinical Neuropharmacology, 28, 106-110.

[25]   Rektor, I., Babic, T., Boothmann, B., Polivka, J., Boroojerdi, B. and Randerath, O. (2009) High Doses of Rotigotine Transdermal Patch: Results of an Open-Label, Dose-Escalation Trial in Patients with Advanced-Stage, Idiopathic Parkinson Disease. Clinical Neuropharmacology, 32, 193-198.